Medisights AI Agents Map CAR-T Referral Gaps in Multiple Myeloma
New York – September 19, 2026 -- Medisights, an AI-native platform for life sciences, has completed a study showing purpose-built AI agents can compress months of qualitative physician research into days while tracking the fast-shifting multiple myeloma treatment landscape.
AI moderators sustain 45-to-60-minute physician interviews to map CAR-T referral logic
Medisights' clinical-grade AI conducted adaptive, humanized conversations with specialists, with interviews routinely running 45 to 60 minutes -- longer engagement than traditional researchers typically secure with physicians. The extended dialogue captured prescribing rationale and geographic variation in CAR-T referral pathways for multiple myeloma, a disease marked by rapidly evolving treatment practices.